|
Re: NLRP3 inhibitors and apabetalone
|
5
|
Resverlogix Corp.
|
Jul 26, 2019 01:32PM
|
|
Peter Libby / You Tube Interview
|
6
|
Resverlogix Corp.
|
Aug 16, 2019 07:59AM
|
|
Re: RVX closes PP...getting US money in?
|
6
|
Resverlogix Corp.
|
Nov 02, 2018 04:34PM
|
|
Re: BET proteins, NFkB and Diabetic Kidney Disease
|
6
|
Resverlogix Corp.
|
Nov 05, 2018 04:48PM
|
|
Re: Losing exclusivity on Aberatirone may not be all that bad for JNJ or ZEL
|
6
|
Zenith Epigenetics
|
Nov 22, 2018 01:42PM
|
|
ZE Slides Up
|
6
|
Zenith Epigenetics
|
Jan 08, 2019 03:58PM
|
|
Re: New article on BET Inhibitors in Cardiovascular Disease
|
6
|
Resverlogix Corp.
|
Jan 30, 2019 01:30PM
|
|
Market Pricing
|
6
|
Resverlogix Corp.
|
Jun 12, 2019 04:41PM
|
|
Re: Antibodies Against Microglial Receptors TREM2 and CD33 Head to Trials
|
6
|
Resverlogix Corp.
|
May 11, 2019 07:04AM
|
|
Re: NLRP3 inhibitors and apabetalone
|
6
|
Resverlogix Corp.
|
Jul 26, 2019 01:24PM
|
|
Re: What else can RVX treat that we don’t know about yet?
|
7
|
Resverlogix Corp.
|
Mar 30, 2019 09:44PM
|
|
Peter Libby
|
9
|
Resverlogix Corp.
|
Aug 14, 2019 09:31AM
|
